Experienced in Scleroderma

Jacques M. Morel

CHU De Montpellier
Montpellier, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Scleroderma
CHU De Montpellier
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Jacques Morel practices in Montpellier, France. Mr. Morel is rated as an Experienced expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Sjogren Syndrome, and Dry Mouth.

His clinical research consists of co-authoring 200 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 2 clinical trials in the study of Scleroderma.

Gender
Male

Locations

CHU de Montpellier
Montpellier, 34000, France
Other Locations
CHU de Reims
Reims, 51092, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug
Study Drug: Clopidogrel Treatment
Study Phase: Phase 2/Phase 3
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Enrollment Status: Recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Other, Drug
Study Drugs: Metformin, Methotrexate
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients
Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Biological, Behavioral
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Enrollment Status: Completed
Publish Date: January 03, 2022
Intervention Type: Biological, Drug
Study Phase: Not Applicable
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Enrollment Status: Withdrawn
Publish Date: May 03, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Not Applicable
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

200 Total Publications

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial.
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial.
Journal: BMJ open
Published: June 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morel's expertise for a condition
ConditionClose
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile